NEW YORK, May 18, 2020 /PRNewswire/ -- Renalytix AI
plc (LSE: RENX), a commercial-stage artificial intelligence-enabled
in vitro diagnostics company, focused on optimizing clinical
management of kidney disease to drive improved patient outcomes and
lower healthcare costs, announces that it has confidentially
submitted a draft registration statement on Form F-1 with the
Securities and Exchange Commission (the "SEC") relating to a
proposed dual-listing and public offering of American Depositary
Shares, each of which will represent one or a number of the
Company's ordinary shares, on the Nasdaq Stock Market (the
"Offering").
The number of securities to be offered and the price for the
proposed Offering have not yet been determined. The Offering is
expected to commence after the SEC completes its review process,
subject to market and other conditions. Shareholders and potential
investors should note that the potential Offering may or may not
proceed.
This press release is being made pursuant to, and in accordance
with, Rule 135 under the Securities Act of 1933, as amended (the
"Securities Act"). This press release does not constitute an offer
to sell or the solicitation of an offer to buy securities, and
shall not constitute an offer, solicitation or sale in any
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of that jurisdiction. Any offers, solicitations or
offers to buy, or any sales of securities will be made in
accordance with the registration requirements of the Securities
Act.
View original
content:http://www.prnewswire.com/news-releases/renalytix-ai-announces-proposed-dual-listing-on-nasdaq-301060982.html
SOURCE RenalytixAI